Last reviewed · How we verify
Betnovat® ointment
Betnovat ointment is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system.
Betnovat ointment is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system. Used for Severe skin conditions such as eczema, psoriasis, and dermatitis.
At a glance
| Generic name | Betnovat® ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Betnovat ointment works by inhibiting the production of pro-inflammatory cytokines and mediators, which contribute to the inflammatory response. This leads to a decrease in the symptoms associated with inflammation, such as redness, swelling, and itching. The exact mechanism of action is not fully understood, but it is thought to involve the suppression of the immune system's response to external stimuli.
Approved indications
- Severe skin conditions such as eczema, psoriasis, and dermatitis
Common side effects
- Skin atrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betnovat® ointment CI brief — competitive landscape report
- Betnovat® ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI